Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01455857 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes
A Phase 3 study, sponsored by Intarcia Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
NCT01455857 is a Phase 3 study that has completed, run by Intarcia Therapeutics. The registered enrollment target is 460 participants.
The verdict
NCT01455857, a Phase 3 study, has completed, sponsored by Intarcia Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
Study Summary
Phase 3 study to examine whether treatment with ITCA-650 60 mcg/day or 40 mcg/day is superior to placebo when added to current therapy in reducing HbA1c in patients with type 2 diabetes.
Interventions
- DRUG ITCA 650
- OTHER ITCA placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01455857
The ClinicalTrials.gov registry entry for NCT01455857 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intarcia Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ITCA 650 is the first listed.
NCT01455857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01455857 about?
NCT01455857 is a clinical study titled "A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes". Phase 3 study to examine whether treatment with ITCA-650 60 mcg/day or 40 mcg/day is superior to placebo when added to current therapy in reducing HbA1c in patients with type 2 diabetes.
What is the current status of trial NCT01455857?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2013-03. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01455857?
The interventions under investigation include: ITCA 650 (DRUG), ITCA placebo (OTHER).
Who is sponsoring clinical trial NCT01455857?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.